HIV, the virus responsible for acquired immunodeficiency syndrome (AIDS), primarily targets CD4+ T cells, essential drivers of the adaptive immune response. Once infected, these cells undergo myriad changes, many of which enable the virus to persist despite the host’s immune defenses. A central puzzle in HIV biology has been how infected cells avoid clearance by innate immune cells, especially myeloid populations such as macrophages and dendritic cells, known for their crucial roles in phagocytosis and antigen presentation.

The new research focuses on sialoglycans, which are oligosaccharides featuring sialic acid residues attached to glycoproteins and glycolipids on cell surfaces. These structures frequently participate in immune regulatory signals, often serving as “self” markers to prevent inappropriate immune attacks. Singh and colleagues demonstrate that HIV infection induces the upregulation of specific sialoglycan motifs on CD4+ T cells, effectively cloaking these cells in a disguise that impairs their recognition and killing by myeloid cells.

Using an array of advanced biochemical and molecular techniques, the researchers characterized the sialoglycan profiles of infected versus uninfected CD4+ T cells. They found a pronounced increase in α2,3- and α2,6-linked sialic acids in infected cells, modifications that are known ligands for Siglec receptors expressed on myeloid immune cells. Siglecs, or sialic acid-binding immunoglobulin-type lectins, function as inhibitory receptors that dampen immune responses upon engagement, thus averting excessive inflammation that could damage host tissues.

The authors established that HIV-induced sialoglycans engage Siglec-9 on macrophages and other myeloid cells, transmitting inhibitory signals that prevent the phagocytic killing of infected T cells. This interaction effectively converts what should be an activating immune encounter into one of tolerance or immune suppression. This finding is particularly significant because it clarifies a molecular basis for the survival of HIV-infected cells despite the presence of immune effectors that are typically capable of clearance.

To validate the functional relevance of sialoglycan-Siglec interactions, the team employed enzymatic and genetic approaches to remove or inhibit sialic acid residues on infected CD4+ T cells. These interventions restored myeloid cell-mediated cytotoxicity, confirming that sialoglycan expression is a critical determinant of immune evasion. Furthermore, blocking Siglec-9 on macrophages similarly enhanced the clearance of infected cells, offering a tantalizing target for therapeutic blockade.

The study’s implications extend beyond HIV biology, highlighting a broader paradigm in viral immune evasion strategies whereby pathogens exploit host glycosylation pathways to escape immune surveillance. Sialoglycans are utilized by several microbes and tumors to manipulate host immunity, and this research firmly places HIV among the pathogens adept at leveraging such molecular mimicry for its survival.

From a clinical perspective, these findings suggest that therapies designed to disrupt the sialoglycan-Siglec axis could enhance the immune system’s ability to eradicate HIV reservoirs, a major obstacle in curing chronic infection. Current antiretroviral treatments can suppress viral replication but fail to eliminate latent or actively infected cells that evade immune detection. Modulating sialoglycan interactions thus offers a complementary strategy to purge hidden or persistent infected cells.

Moreover, understanding the biochemical pathways by which HIV induces sialoglycan expression may enable the development of inhibitors targeting the enzymes responsible for these modifications. Sialyltransferases, the enzymes that attach sialic acid residues to glycoconjugates, represent potential drug targets. Interrupting their activity could strip infected cells of their protective sugar coats, rendering them vulnerable to immune clearance.

In addition to therapeutic applications, the study has diagnostic ramifications. Monitoring sialoglycan profiles on circulating CD4+ T cells may serve as a biomarker for identifying infected cells or assessing treatment efficacy. Such glycan-based biomarkers could enhance the precision of HIV diagnostics and help stratify patients based on their immune evasion status.

Importantly, the work underscores the complex interplay between virus and host at the molecular level, where HIV manipulates host cell machinery to subvert immune defense without triggering excessive immune activation that could lead to cell death or immune exhaustion. This fine-tuned balance contributes to the virus’s persistence and pathogenesis, explaining in part why HIV remains a formidable global health challenge despite decades of research.

The study employed cutting-edge methodologies including mass spectrometry-based glycomics, flow cytometry with lectin probes, gene-editing to modulate glycosylation enzymes, and functional immune assays with primary human macrophages. These interdisciplinary approaches provided a comprehensive picture of how HIV reshapes the glycan landscape of infected cells and how this reshaping dictates immune outcomes.

Future research will need to unravel how HIV regulates the expression of sialoglycans—whether through direct viral protein actions, alterations in host gene transcription, or metabolic changes driving glycan biosynthesis. Understanding these upstream events may reveal new checkpoints for intervention beyond the direct blockade of sialoglycan interactions.

In summary, the discovery that HIV co-opts sialoglycans on infected CD4+ T cells to evade myeloid cell-mediated killing represents a paradigm shift in our grasp of viral immune evasion. It not only clarifies fundamental aspects of HIV biology but also carves new paths toward therapeutic strategies aimed at neutralizing the virus’s stealth tactics. As the global scientific community strives toward an HIV cure, these insights provide critical molecular targets to help unlock the virus’s defenses and harness the full power of the immune system.

This novel insight into the glyco-immune interface illustrates the increasingly appreciated role of glycobiology in infectious disease research. As we deepen our understanding of the sugar-based language that underpins immune regulation, innovative treatments exploiting glycan pathways might soon transform the management of chronic viral infections like HIV.

The publication by Singh, Islam, Liu et al. marks a milestone in translational immunology, offering hope for more effective vaccines and immunotherapies that prevent HIV persistence. By elucidating the molecular cloak that shields infected cells, this work galvanizes the scientific quest to outmaneuver HIV’s elaborate survival strategies once and for all.

Subject of Research:

The study investigates the molecular mechanisms by which HIV-infected CD4+ T cells evade immune clearance, specifically focusing on the role of virus-induced sialoglycans and their interaction with Siglec receptors on myeloid immune cells.

Article Title:

HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killing.

Article References:

Singh, S., Islam, S.M.S., Liu, R. et al. HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killing. Nat Commun (2025). https://doi.org/10.1038/s41467-025-66540-y

Image Credits: AI Generated

The concept of viral latency in HIV infection has long been a significant barrier to curing the disease. HIV integrates its genetic material into host immune cells, particularly CD4+ T cells, where it can lie dormant for extended periods. During latency, the virus does not produce new copies of itself, evading both immune detection and antiviral drugs. The Johns Hopkins team, led by Dr. Fabio Romerio, focused on AST, a molecular transcript encoded by the HIV genome on the strand opposite to the one that produces viral proteins. AST appears to be part of a naturally occurring regulatory mechanism that restricts viral gene expression and maintains the virus in a silent state.

In their recent study, researchers genetically engineered HIV-infected CD4+ T cells to overexpress AST, adding a genetic element designed to amplify AST production within the cells. This manipulation led to a significant decline in viral transcriptional activity. They used green fluorescent protein (GFP) as a surrogate marker for HIV gene expression, observing that cells with elevated AST levels exhibited nearly undetectable GFP fluorescence, indicating deep viral dormancy. This finding underscores AST’s potential as a molecular switch to silence viral replication robustly and sustainably.

Further molecular analysis focused on dissecting the structure-function relationships of the AST molecule. Utilizing advanced laser-based cytometry techniques, the team identified specific regions of AST critical for its ability to bind and recruit host proteins that enforce viral silencing. By creating a series of targeted mutations within the AST sequence, the researchers delineated domains essential for initiating and maintaining latency. These insights are pivotal for guiding the design of gene therapies that could specifically enhance the virus’s natural latency mechanisms.

Crucially, the study extended beyond laboratory-grown cell lines to examine the behavior of AST in CD4+ T cells derived from individuals living with HIV. These cells were transiently transfected with DNA encoding AST through a method that permeabilizes cell membranes, enabling direct delivery of genetic material. This approach proved successful in inducing viral latency, with HIV remaining dormant for at least four days post-treatment. The transient nature of AST expression, which declined as the introduced DNA fragmented, highlights the need for stable gene therapy methods to sustain this state in patients.

The biomedical significance of this research is heightened by the limitations of current antiretroviral therapies (ART). While ART effectively suppresses active viral replication, it does not eradicate the latent reservoir. Patients must adhere to lifelong medication regimens, which can lead to cumulative side effects and the risk of viral rebound if interrupted. The Johns Hopkins team’s vision is to develop a single-dose gene therapy strategy that boosts intrinsic viral latency pathways through AST, offering a durable functional cure and drastically reducing treatment burdens.

Mechanistically, the antisense transcript likely modulates chromatin remodeling and recruits epigenetic regulators to the integrated viral genome. This suppresses transcription of viral genes, maintaining the genome in a repressed configuration that prevents reactivation. Understanding this precise interplay between viral RNA transcripts and host cell machinery opens new doors for targeting HIV reservoirs that have traditionally been resistant to conventional therapies.

The research, which was funded primarily by the National Institutes of Health and supported by the American Foundation for AIDS Research, involved multidisciplinary collaboration among molecular biologists, immunologists, and clinicians. Alongside Drs. Fabio Romerio and Rui Li at Johns Hopkins, scientists from Massachusetts General Hospital and George Mason University contributed to refining the experimental approaches and validating the findings in patient-derived cells.

Looking forward, the integration of AST-based gene therapies into clinical practice will require overcoming significant hurdles, including efficient and safe delivery of genetic materials to patient immune cells, long-term expression and stability of AST, and comprehensive assessment of potential off-target effects. However, the proof-of-concept established by this study marks a critical step toward a new class of therapeutics aimed at functionally curing HIV by harnessing its own genetic machinery.

The broader impact of these findings also resonates with the global burden of HIV/AIDS, where nearly 40 million people live with the virus, and hundreds of thousands succumb each year despite the availability of effective therapies. A gene therapy that induces a permanent dormant state could transform public health strategies, reduce transmission rates, and alleviate the financial and societal costs associated with chronic antiviral medication.

In conclusion, the innovative exploitation of the HIV-encoded antisense transcript to enforce viral latency signifies a promising frontier in HIV research. By manipulating viral RNA to maintain the virus in a deep sleep, scientists are paving the way for transformative therapies that could one day liberate patients from the necessity of lifelong antiretroviral regimens. As this research progresses toward clinical translation, it holds the potential to redefine how we understand and ultimately manage HIV infection.

Subject of Research: Molecular mechanisms of HIV latency mediated by antisense transcript (AST) and gene therapy approaches to induce long-term viral dormancy.

Article Title: Untitled in source content (not provided).

News Publication Date: May 9 (year not specified, refers to journal publication date).

Web References:

• Science Advances article
• Johns Hopkins Medicine study page
• HIV statistics – HIV.gov
• WHO HIV/AIDS data

References: See the Science Advances publication and prior studies by Johns Hopkins team.

Keywords: HIV latency, antisense transcript, viral dormancy, gene therapy, CD4+ T cells, viral transcription, HIV replication suppression, molecular biology, viral reservoirs